



Audentes Therapeutics (USA): Constituent Deletion

Changes in Russell Equal Weight Index Series

15 January 2020

Following the completion of the tender offer of Audentes Therapeutics (USA, constituent) by Astellas Pharma Inc., please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
Russell 2000 Equal Weight	20 January 2020

*In the absence of an active market, Audentes Therapeutics will be removed from the index at the merger terms of \$60.00 USD.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2020 FTSE Russell